Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care

•Cabozantinib is approved for use in patients with advanced renal cell carcinoma.•Cabozantinib is associated with high interpatient variability in drug clearance.•Patients may require dose reduction to achieve optimal cabozantinib exposure.•Exposure-response models predict that dose reductions improve tolerability.•Appropriate dose reductions are predicted to have minimal impact on efficacy.